This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baron, S. D.
Right arrow Articles by Metzger, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baron, S. D.
Right arrow Articles by Metzger, D. W.

 Previous Article  |  Next Article 

Infection and Immunity, May 2007, p. 2152-2162, Vol. 75, No. 5
0019-9567/07/$08.00+0     doi:10.1128/IAI.01606-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Inactivated Francisella tularensis Live Vaccine Strain Protects against Respiratory Tularemia by Intranasal Vaccination in an Immunoglobulin A-Dependent Fashion{triangledown}

Shawn D. Baron, Rajendra Singh, and Dennis W. Metzger*

Center for Immunology & Microbial Disease, Albany Medical College, Albany, New York 12208

Received 4 October 2006/ Returned for modification 6 December 2006/ Accepted 2 February 2007

Francisella tularensis is a gram-negative intracellular bacterium that is considered to be a potential category A biological weapon due to its extreme virulence. Although vaccination with the attenuated live vaccine strain (LVS) of F. tularensis can protect against lethal challenge, use of inactivated or subunit forms as vaccine candidates for induction of protective antibody responses has not been fully evaluated. In the present study, we examined whether immune protection in the lung could be stimulated by intranasal administration of inactivated LVS together with interleukin-12 (IL-12) as an adjuvant. LVS was inactivated by heat, paraformaldehyde treatment, or exposure to UV, and inactivation of the preparations was confirmed by assessing bacterial growth and the survival of mice after direct inoculation. We found that mucosal vaccination with inactivated LVS provided 90 to 100% protection in mice after lethal intranasal challenge with 104 CFU of LVS, and this protection was dependent on inclusion of exogenous IL-12 during vaccine administration. Survival of vaccinated mice after live bacterial challenge was correlated with reduced bacterial burden, decreased pulmonary inflammation, increased serum antibody titers, and lower levels of gamma interferon (IFN-{gamma}), tumor necrosis factor alpha, and IL-6 in the lungs, livers, and spleens. Whereas NK cells were primarily responsible for the production of IFN-{gamma} in unvaccinated, challenged animals, vaccinated mice had increased levels of lung IFN-{gamma}+ CD4+ T cells after challenge. Significantly, mice genetically deficient in immunoglobulin A (IgA) expression were unable to survive lethal challenge after vaccination. These results are the first results to demonstrate that IgA-mediated protection against lethal respiratory tularemia occurs after mucosal vaccination with inactivated F. tularensis LVS.


* Corresponding author. Mailing address: Center for Immunology & Microbial Disease, MC-151, Albany Medical College, 47 New Scotland Avenue, Albany, NY 12208. Phone: (518) 262-6750. Fax: (518) 262-6053. E-mail: metzged{at}mail.amc.edu

{triangledown} Published ahead of print on 12 February 2007.

Editor: J. N. Weiser


Infection and Immunity, May 2007, p. 2152-2162, Vol. 75, No. 5
0019-9567/07/$08.00+0     doi:10.1128/IAI.01606-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Bitsaktsis, C., Rawool, D. B., Li, Y., Kurkure, N. V., Iglesias, B., Gosselin, E. J. (2009). Differential Requirements for Protection against Mucosal Challenge with Francisella tularensis in the Presence versus Absence of Cholera Toxin B and Inactivated F. tularensis. J. Immunol. 182: 4899-4909 [Abstract] [Full Text]  
  • Ray, H. J., Cong, Y., Murthy, A. K., Selby, D. M., Klose, K. E., Barker, J. R., Guentzel, M. N., Arulanandam, B. P. (2009). Oral Live Vaccine Strain-Induced Protective Immunity against Pulmonary Francisella tularensis Challenge Is Mediated by CD4+ T Cells and Antibodies, Including Immunoglobulin A. CVI 16: 444-452 [Abstract] [Full Text]  
  • Chiavolini, D., Weir, S., Murphy, J. R., Wetzler, L. M. (2008). Neisseria meningitidis PorB, a Toll-Like Receptor 2 Ligand, Improves the Capacity of Francisella tularensis Lipopolysaccharide To Protect Mice against Experimental Tularemia. CVI 15: 1322-1329 [Abstract] [Full Text]  
  • Huntley, J. F., Conley, P. G., Rasko, D. A., Hagman, K. E., Apicella, M. A., Norgard, M. V. (2008). Native Outer Membrane Proteins Protect Mice against Pulmonary Challenge with Virulent Type A Francisella tularensis. Infect. Immun. 76: 3664-3671 [Abstract] [Full Text]  
  • Rawool, D. B., Bitsaktsis, C., Li, Y., Gosselin, D. R., Lin, Y., Kurkure, N. V., Metzger, D. W., Gosselin, E. J. (2008). Utilization of Fc Receptors as a Mucosal Vaccine Strategy against an Intracellular Bacterium, Francisella tularensis. J. Immunol. 180: 5548-5557 [Abstract] [Full Text]  
  • Thakran, S., Li, H., Lavine, C. L., Miller, M. A., Bina, J. E., Bina, X. R., Re, F. (2008). Identification of Francisella tularensis Lipoproteins That Stimulate the Toll-like Receptor (TLR) 2/TLR1 Heterodimer. J. Biol. Chem. 283: 3751-3760 [Abstract] [Full Text]  
  • Wolf, A. J., Desvignes, L., Linas, B., Banaiee, N., Tamura, T., Takatsu, K., Ernst, J. D. (2008). Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. JEM 205: 105-115 [Abstract] [Full Text]  
  • Kirimanjeswara, G. S., Golden, J. M., Bakshi, C. S., Metzger, D. W. (2007). Prophylactic and Therapeutic Use of Antibodies for Protection against Respiratory Infection with Francisella tularensis. J. Immunol. 179: 532-539 [Abstract] [Full Text]